Skip to main content
GutCited

Lactobacillus rhamnosus GG para Irritable Bowel Syndrome (IBS)

B

Several RCTs show improvement in IBS symptoms, particularly bloating and abdominal pain. Effect strongest in IBS-D subtype. Results not uniform across all IBS subtypes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Conclusão

Several RCTs show improvement in IBS symptoms, particularly bloating and abdominal pain. Effect strongest in IBS-D subtype. Results not uniform across all IBS subtypes.

Key Study Findings

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None vs: placebo Outcome: improvement in key IBS symptoms Efeito: None None

População: patients with IBS from 32 RCTs evaluating 10 probiotic strains

Randomized Controlled Trial 3 weeks Double-blind
Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review …
Dose: None vs: Placebo Outcome: Pain outcomes Efeito: None None

População: IBS patients

Systematic Review n=3
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic …
Dose: None vs: None Outcome: Abdominal pain frequency/intensity, constipation Efeito: None None

População: Children with FAPD or functional constipation

Systematic Review
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Dose: various probiotic strains vs: placebo Outcome: IBS symptom improvement in children Efeito: LGG showed benefit in some studies None

População: Children with IBS

Review
Probiotic Bacterial and Fungal Strains: Claims with Evidence.
Dose: None vs: None Outcome: None Efeito: None None

População: Various populations (probiotic claims review)

Review
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Dose: None vs: None Outcome: None Efeito: None None

População: IBD patients

Key Statistics

8

Estudos

1200

Participantes

Positive

B

Nota

Referenced Papers

Digestive diseases (Basel, … 2016 37 citações
Journal of pediatric … 2016 19 citações
Asia Pacific journal … 2006 45 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:
10-20 billion CFU/day
ibssupport:
10 billion CFU/day for 4-8 weeks
aadprevention:
10-20 billion CFU/day (start with antibiotic, continue 7 days after)

Limite superior: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Dosagens Estudadas em Pesquisas

Dosagem Duração Efeito N
None -- Positive --
None 3 weeks Positive --
None -- Mixed 3
various probiotic strains -- Mixed --
None -- Mixed --
None -- Mixed --
None -- Mixed --
None 26.0 weeks Mixed --

Melhor horário: On an empty stomach or 30 minutes before meals for optimal survival

Safety & Side Effects

Efeitos Colaterais Relatados

  • Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
  • Rare reports of bacteremia in severely immunocompromised individuals
  • Occasional loose stools during adjustment period
  • Very rare: systemic infection in critically ill patients with central venous catheters

Interações Conhecidas

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (theoretical risk of infection in immunocompromised patients)
  • Antifungals (no known interaction but may affect gut flora balance)

Ingestão máxima tolerável: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Lactobacillus rhamnosus GG help with Irritable Bowel Syndrome (IBS)?
Based on 8 studies with 1,200 participants, there is moderate evidence from clinical studies that Lactobacillus rhamnosus GG may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus rhamnosus GG should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 8 peer-reviewed studies with 1,200 total participants. The overall direction of effect is positive.

Related Evidence

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.